Fast & Scalable Continuous Manufacturing of Viruses for Gene Therapies and Vaccines

Currently, there is serious lack of supply of virus particles for gene therapies and for vaccines in case of a pandemic emergency (influenza, coronavirus disease). Additionally, manufacturing custom-made viruses can cost biotech firms a third or more of their development budget.


Expanding manufacturing capacity with traditional technologies will not improve the current situation:

It is estimated that a tenfold improvement in virus manufacturing is needed to enable the growth of the gene therapy market

($11 bn by 2025).

ContiVir is developing highly efficient virus production technologies that have the potential to resolve these issues.

Learn more about Our Technologies.